{
    "title": "Sanofi raises outlook but key eczema drug disappoints investors",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4745576/Sanofi-raises-outlook-strong-Q2-sales-growth.html",
    "date": "2017-07-31",
    "keywords": [
        "percent",
        "dupixent",
        "sanofi",
        "forecast",
        "quarter",
        "growth",
        "drug",
        "regeneron",
        "consensus",
        "biotech",
        "product",
        "revenue",
        "back",
        "partner",
        "monday",
        "drugmaker",
        "share",
        "year",
        "stock",
        "york",
        "executive",
        "olivier",
        "brandicourt",
        "uptake",
        "market",
        "stanley",
        "note",
        "closer",
        "food",
        "administration",
        "medicine",
        "atopic",
        "dermatitis",
        "eczema",
        "march",
        "launch",
        "asthma",
        "bernstein",
        "figure",
        "medication",
        "recommendation",
        "medicines",
        "agency",
        "panel",
        "month",
        "thomson",
        "drive",
        "reliance",
        "highmargin",
        "biologic",
        "income",
        "exchange",
        "line",
        "partnership",
        "business",
        "profit",
        "mix",
        "momentum",
        "europe",
        "division",
        "pricing",
        "pressure",
        "sudip",
        "kargupta",
        "croft"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}